Abstract
Zirconium-89 (Zr-89) has recently drawn significant interest to be a promising metallo-radionuclide for use in immuno-PET due to favorable decay characteristics. Despite all efforts that have been done over the last few years in the development of procedures for large-scale production and purification of Zr-89 and its stable coupling to mAbs as well as successful preclinical and clinical Zr-89 immuno-positron emission tomography (PET) studies, there is still gap for exploring new peptide-based pharmaceuticals radiolabeled with Zr-89 and the development of Zr-89 immuno-PET imaging protocols. The objectives of this study is intended to review the recent development and optimization of Zr-89 production and to discuss the Zr-89 immuno-PET clinical imaging applications for breast cancer. In addition, the Zr-89 PET imaging safety and protocols as well as the potential use of Zr-89 in 3-gamma PET Imaging are reviewed.